Innoviva (INVA) Competitors

Alkermes (NASDAQ:ALKS) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Is ALKS or INVA more profitable?

Alkermes has a net margin of 23.15% compared to Innoviva's net margin of -16.15%. Alkermes' return on equity of 24.86% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	23.15%	24.86%	17.14%
Innoviva	-16.15%	15.77%	8.41%

Which has preferable earnings & valuation, ALKS or INVA?

Alkermes has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.56B	2.81	$367.07M	$2.08	12.76
Innoviva	$358.71M	3.19	$23.39M	-$1.01	-18.07

Which has more volatility and risk, ALKS or INVA?

Alkermes has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.

Do analysts recommend ALKS or INVA?

Alkermes currently has a consensus target price of $41.08, suggesting a potential upside of 54.74%. Innoviva has a consensus target price of $40.33, suggesting a potential upside of 121.04%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
Innoviva	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer ALKS or INVA?

In the previous week, Alkermes had 12 more articles in the media than Innoviva. MarketBeat recorded 18 mentions for Alkermes and 6 mentions for Innoviva. Innoviva's average media sentiment score of 1.67 beat Alkermes' score of 0.97 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do institutionals & insiders have more ownership in ALKS or INVA?

95.2% of Alkermes shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 4.4% of Alkermes shares are held by company insiders. Comparatively, 2.3% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Alkermes beats Innoviva on 12 of the 17 factors compared between the two stocks.